Developmental and Epileptic Encephalopathies (DEEs) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Developmental and Epileptic Encephalopathies (DEEs) Emerging Therapy and TPP Insights

Thelansis's "Developmental and Epileptic Encephalopathies (DEEs) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Developmental and Epileptic Encephalopathies (DEEs) Overview

Developmental and epileptic encephalopathies (DEEs) are a heterogeneous group of severe, pediatric-onset neurodevelopmental syndromes characterized by drug-resistant epilepsy, developmental stagnation or regression, and cognitive deficits. Unlike classic epilepsies, DEEs damage neurodevelopment through both the underlying genetic or structural etiology and the continuous, disruptive electrographic activity itself. Syndromic archetypes like Dravet, Lennox-Gastaut, and SCN2A/8A mutations are routinely confirmed via advanced multigene panels, which have replaced broad diagnostic guesswork. While standard broad-spectrum antiseizure medications (such as fenfluramine and cannabidiol) provide baseline symptom mitigation, the field has aggressively moved into an era of genotype-specific precision pharmacology. The current landscape is anchored by targeted central nervous system therapeutics designed to address specific ion channel variants. A landmark shift involves relutrigine, a selective inhibitor of persistent sodium currents under FDA Priority Review with a target action date of December 27, 2026, for SCN2A and SCN8A DEEs, complemented by its broad-DEE Phase 3 EMERALD trial. Concurrently, the antisense oligonucleotide (ASO) pipeline has achieved dramatic success, led by zorevunersen (STK-001) for Dravet syndrome and elsunersen, which recently demonstrated a 77% placebo-adjusted monthly seizure reduction in early-onset SCN2A-DEE. These targeted molecular frameworks offer the first true disease-modifying prospects to stabilize both seizure activity and underlying cognitive trajectories.

Key Highlights

• In Germany, the DEE prevalence patient pool is projected to increase from approximately 16,265 cases in 2025 to 16,395 by 2035.
• DEE represents a group of severe neurological disorders characterized by refractory seizures and developmental impairment.
• Genetic testing is increasingly enabling earlier diagnosis and precision treatment selection.
• Significant unmet need remains due to persistent seizure burden and cognitive dysfunction.
• Emerging gene-targeted and disease-modifying therapies are expanding future treatment opportunities.

Market Overview

• The Spain DEE market is projected to grow from approximately $180 MN to $480 MN by 2035.
• Market growth is supported by:
• Increasing adoption of novel anti-seizure medications
• Expansion of precision medicine and genetic therapies
• Market expansion is driven by high unmet need and increasing treatment intensity.
• Future growth will depend on gene therapies and innovative disease-modifying treatment approaches.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Longboard Pharmaceuticals
• Praxis Precision Medicines
• Neurocrine Biosciences
• Bright Minds Biosciences Pty Ltd.
• Encoded Therapeutics